Financials data is unavailable for this security.
View more
Year on year Liaoning Chengda Biotechnology Co Ltd 's revenues fell -3.58% from 1.81bn to 1.75bn. This along with an increase in the cost of goods sold expense has contributed to a reduction in net income from 714.02m to 465.92m, a -34.75% decrease.
| Gross margin | 81.24% |
|---|---|
| Net profit margin | 20.04% |
| Operating margin | 25.61% |
| Return on assets | 3.54% |
|---|---|
| Return on equity | 3.71% |
| Return on investment | 3.66% |
More ▼
Cash flow in CNYView more
In 2023, cash reserves at Liaoning Chengda Biotechnology Co Ltd fell by 1.25bn. However, the company earned 677.01m from its operations for a Cash Flow Margin of 38.68%. In addition the company used 1.40bn on investing activities and also paid 522.69m in financing cash flows.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 22.93 |
|---|---|
| Tangible book value per share | 21.37 |
More ▼
Balance sheet in CNYView more
| Current ratio | 18.49 |
|---|---|
| Quick ratio | 17.34 |
| Total debt/total equity | 0.0019 |
|---|---|
| Total debt/total capital | 0.0019 |
More ▼
Growth rates in CNY
Year on year, both dividends per share and earnings per share excluding extraordinary items growth dropped -20.00% and -34.68%, respectively. Additionally, five year annualized earnings per share growth is in-line with the industry average relative to its peers.
| Div yield(5 year avg) | 1.41% |
|---|---|
| Div growth rate (5 year) | -- |
| Payout ratio (TTM) | 93.69% |
| EPS growth(5 years) | -5.54 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -47.28 |
More ▼
